But what exactly is the Nuria Millan testing repack protocol? Why has it become indispensable in regulatory compliance? And how can your facility implement it to ensure sterility and stability? This comprehensive guide covers everything you need to know. Before diving into Nuria Millan’s specific contributions, it is essential to understand the concept of testing repack .
Audit your current repack testing protocol today. If it does not include media fill simulation, stability studies, and container closure integrity testing, you are not truly following the Nuria Millan standard. Upgrade your process—and safeguard your patients. For more information on Nuria Millan’s training programs and the latest guidelines on testing repack, consult the USP <797> compendium or visit accredited compounding education centers. nuria millan testing repack
Until then, the methodology remains the most robust, defensible, and patient-safe approach available today. Conclusion: Don’t Just Repack—Validate, Verify, and Protect The phrase “Nuria Millan testing repack” has become shorthand in compounding circles for uncompromising quality. It reminds us that repackaging is not a clerical task—it is an aseptic manufacturing process that demands the same rigor as a pharmaceutical factory. But what exactly is the Nuria Millan testing repack protocol
Whether you are a hospital pharmacist, a lab manager, or a regulatory inspector, adopting Millan’s principles means choosing active prevention over reactive correction. Test not just to pass an inspection, but because every syringe, vial, or bag you repackage will eventually enter a patient’s bloodstream. This comprehensive guide covers everything you need to know
Millan’s philosophy is simple but profound: “Testing without understanding the process is just a snapshot. A repack testing protocol must be dynamic, risk-based, and continuous.” Most compounding facilities rely on periodic, batch-based testing. They repackage a batch of syringes, send a few samples to a lab, and assume the entire batch is safe if those samples pass. Nuria Millan challenges this approach. She argues that end-point testing is necessary but insufficient.